Acute Respiratory Viruses
COVID-19

COVID-19

Microbiology

Additional Information

COVID-19 signs, symptoms and severity of disease: A clinical guide. Government of Canada. Accessed online October 31, 2023 from: COVID-19 signs, symptoms and severity of disease: A clinician guide - Canada.ca

Access to antiviral treatments for COVID-19 in the community. Ontario Health. Sep 25, 2023. Accessed online October 31, 2023 from: Access to antiviral treatments for COVID-19 in the community (ontariohealth.ca)

The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2100433.

Salama C, Han J, Yau L et al (2020) Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. https://doi.org/10.1056/NEJMoa2030340

Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group Therapeutic Management of Adult Patients with COVID-19. Accessed online August 30, 2021 from: https://covid19-sciencetable.ca/wp-content/uploads/2021/08/CPGSummary_final.pdf

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. Preprint from Feb 11, 2021. DOI: https://doi.org/10.1101/2021.02.11.21249258

Approved: May 2021

Revised:

  • Aug 2021 (updated tocilizumab dosing)
  • Jan 2022 (updated COVID guidance links)
  • Apr 2022 (updated COVID guidance links)
  • May 2022 (added interaction reference)
  • Oct 2023